News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alnylam Pharmaceuticals (ALNY) Announces Manufacturing Agreement With Dowpharma (DOW) For RNAi Therapeutics



10/19/2005 5:13:09 PM

CAMBRIDGE, Mass. & MIDLAND, Mich.--(BUSINESS WIRE)--March 29, 2005--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Dowpharma(SM), a business unit of The Dow Chemical Company (NYSE: DOW), announced today an agreement for the manufacture and supply of candidate RNAi therapeutics for Alnylam's lead development programs in age-related macular degeneration (AMD) and respiratory syncytial virus (RSV) infection. Dowpharma will manufacture short interfering RNAs (siRNAs), the molecules that induce RNAi, for use in clinical trials. "This agreement is an important step in our transition to a clinical-stage company as we rapidly advance multiple RNAi therapeutic candidates into human trials," said John Maraganore, Ph.D., President and Chief Executive Officer of Alnylam Pharmaceuticals. "Dowpharma is a high-quality partner who will provide Alnylam access to large-scale synthesis and purification of siRNAs necessary for clinical development."

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES